Goodwin advised resTORbio in the transaction resTORbio, Inc. (NASDAQ:TORC), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of…
resTORbio’s $97.8 Million Initial Public Offering
